Heterocyclic Compounds

Matches 401 - 450 out of 9,425	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >

Document	Document Title
WO/2023/018699A1	SELECTIVE KRAS INHIBITORS The present embodiments provide compounds of Formula (I), compositions of the compounds, and methods for treating diseases such as cancer.
WO/2023/018648A1	PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a...
WO/2023/018960A1	IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES The invention provides novel improved methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
WO/2023/015559A1	MACROCYCLE COMPOUNDS AS INHIBITORS OF RAS The present disclosure discloses a compound, or a pharmaceutically acceptable salt thereof having the structure of Formula (I), and pharmaceutical compositions including the same, that are inhibitors of one or more RAS proteins and are u...
WO/2023/012364A1	PHOTORESPONSIVE NONFULLERENE ACCEPTORS OF THE A-D-A'-D-A TYPE FOR USE IN OPTOELECTRONIC DEVICES A compound of formula (I), A1 is a divalent heteroaromatic electron-accepting group; A2 and A3 are each independently a monovalent electron-accepting group; D1 and D2 independently in each occurrence is an electron-donating group; B1 and...
WO/2023/015240A1	TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS Provided herein are tricyclic fused pyrimidine compounds, and pharmaceutically acceptable salts thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
WO/2023/012365A1	PHOTORESPONSIVE ASYMMETRIC NONFULLERENE ACCEPTORS OF THE A-D-A'-D-A TYPE FOR USE IN OPTOELECTRONIC DEVICES A compound of formula (I), A1 is an electron-accepting group; D1 and D2 independently in each occurrence is an electron-donating group; A1, A2 and A3 are each independently an electron-accepting group; B1 and B2 in each occurrence are in...
WO/2023/012366A1	PHOTORESPONSIVE NONFULLERENE ACCEPTORS OF THE A-D-A'-D-A TYPE FOR USE IN OPTOELECTRONIC DEVICES A compound of formula (I), A1 is a divalent heteroaromatic electron-accepting group comprising at least 3 fused aromatic rings, or has a modelled LUMO of more than 2.70 eV from vacuum level. A2 and A3 are each independently a monovalent ...
WO/2023/012363A1	PHOTOACTIVE NONFULLERENE ACCEPTORS OF THE A-D-A'-D-A TYPE FOR USE IN OPTOELECTRONIC DEVICES A compound of formula (I), D1 and D2 are electron-donating groups; A2 and A3 are electron-accepting groups; B1 and B2 are bridging groups; x1 and x2 are 0, 1, 2 or 3; yl and y2 are at least 1; zl and z2 are 0, 1, 2 or 3; and A1 is a grou...
WO/2023/011540A1	FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF A fused ring compound, a pharmaceutical composition, and an application thereof. Provided is a fused ring compound shown in formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and good SOS1 inhibit...
WO/2023/007185A1	IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, and/or N-oxide thereof. The invention also relates to the processes for the preparation of those...
WO/2023/004356A2	AZAINDOLE CYANINE DYES, USES, AND METHODS OF PREPARATION The present disclosure relates to new and useful azaindole cyanine (pyrrolo pyridine cyanine) compounds. Use of the compounds as dyes that operate in the far-red and near-IR spectral region in biological imaging, and methods of making th...
WO/2023/001123A1	NEW PYRIDOPYRIMIDINE DERIVATIVE Provided in the present invention are a new pyridopyrimidine derivative, a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer, and a pharmaceutical composition containing same and the use thereof. The compound of th...
WO/2023/001794A1	SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoi...
WO/2023/287896A1	TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
WO/2023/288254A1	HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are MAP4K1 inhibitors, which can be used t...
WO/2023/284730A1	ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS The present disclosure provides certain alkylidenyl derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
WO/2023/288264A1	MAP4K1 INHIBITORS One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to trea...
WO/2023/283372A1	COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS This disclosure relates to compounds of Formula (A): Formula (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently att...
WO/2023/280283A1	COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF The present invention relates to a compound used as an SHP2 inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula I', wherein the definitions of each group and each s...
WO/2023/280073A1	METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND A method for preparing a nitrogen-containing polycyclic fused ring compound, and an intermediate of the compound. By means of the preparation method, a compound of formula I and an intermediate thereof can be synthesized in a high-yield,...
WO/2023/283610A1	COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalen...
WO/2023/275230A1	5-OXO-PYRIDO[2,3-D]PYRIDAZIN-6(5H)-YL ACETAMIDES The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
WO/2022/250170A9	SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D and/or G12V mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating ca...
WO/2023/276918A1	COMPOUND, ELECTRONIC BARRIER MATERIAL, AND ORGANIC SEMICONDUCTOR ELEMENT AND COMPOUND A compound represented by the following general formula is an excellent electronic barrier material. X represents a donor group; R1 to R6 represent substituents; and n1 to n6 represent integers greater than or equal to 0 and less than or...
WO/2023/274383A1	KRAS G12D INHIBITOR AND USE THEREOF A KRAS inhibitor compound represented by formula (I), and an isomer or a pharmaceutically acceptable salt thereof. The compound represented by formula (I) and the composition thereof can effectively treat diseases related to KRAS mutation.
WO/2023/274310A1	CRYSTAL FORM OF PURINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF A crystal form of substituted purine derivatives and pharmaceutical compositions thereof, preparation methods, and uses for preparing a DNA-PK inhibitor are related to. Specifically, a crystal form of a compound represented by formula (A...
WO/2023/276753A1	ORGANIC PHOTODETECTOR, AND ORGANIC SEMICONDUCTOR COMPOUND USED FOR SAME The purpose of the present invention is to provide an organic photodetector that realizes high conversion efficiency.　The organic photodetector has a structure in which a base, a cathode, an active layer, and an anode are arranged in t...
WO/2022/268088A1	TRICYCLIC COMPOUND USED AS GPR84 ANTAGONIST The present invention relates to a tricyclic compound used as a GPR84 antagonist, and in particular relates to a tricyclic compound having a structure shown in formula I, and tautomers, stereoisomers, hydrates, solvates, pharmaceutically...
WO/2022/271684A1	DIACYLGLYERCOL KINASE MODULATING COMPOUNDS The application relates to diacylglycerol kinase modulating compounds of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B viru...
WO/2022/267801A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE The present application relates to an organic compound, an organic electroluminescent device comprising the organic compound, and an electronic device comprising the organic electroluminescent device. The structure of the organic compoun...
WO/2022/271612A1	HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
WO/2022/269531A1	HER2 MUTATION INHIBITORS This invention relates to compounds of Formula (I): (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L2, R1, R2, R3, R4, and n are as defined herein. The invention fur...
WO/2022/270592A1	ELECTRON BARRIER MATERIAL, ORGANIC SEMICONDUCTOR ELEMENT AND COMPOUND This compound represented by a general formula is useful as an electron barrier material. R1 through R5 are a deuterium atom, a substituent other than a cyano group; n1, n3, n5 are 0-4; n2 is 0-3; n4 is 0-2; X is O or S; and Ar is a mono...
WO/2022/271823A1	MUTANT KRAS MODULATORS AND USES THEREOF The disclosure includes compounds of Formula (1)-(4) wherein each of Warhead, R1, R2, R3, L1, L2, L3, L4, L5, L6, R, Q1, Q2, Q3, W1, W2, m, n, and i, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoi...
WO/2022/270113A1	ORGANIC ELECTROLUMINESCENT ELEMENT Provided is an organic electroluminescent element by which high light-emission efficiency can be obtained even in a case in which the LUMO level of a fluorescent material is lower than the LUMO level of a delayed fluorescent material. Th...
WO/2022/271659A1	DIACYLGLYERCOL KINASE MODULATING COMPOUNDS The application relates to diacylglycerol kinase modulating compounds of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B viru...
WO/2022/271650A1	DIACYLGLYERCOL KINASE MODULATING COMPOUNDS The application relates to diacylglycerol kinase modulating compounds of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B viru...
WO/2022/270591A1	COMPOUND, COMPOSITION, HOST MATERIAL, ELECTRON BARRIER MATERIAL AND ORGANIC LIGHT EMITTING ELEMENT An organic light emitting element which uses a compound represented by the general formula has high thermal stability and excellent light emission characteristics. Each of R1 to R7 represents a hydrogen atom, a deuterium atom, an alkyl g...
WO/2022/262686A1	KRAS G12D INHIBITORS Disclosed are novel compounds which are KRAS G12D inhibitors, their synthesis and their use for treating diseases or conditions, such as cancer, and in particular for inhibiting the activity of KRAS G12D, pharmaceutical compositions comp...
WO/2022/262310A1	METHOD FOR SYNTHESIZING BTBF AROMATIC AMINE DERIVATIVES The present invention provides a method for synthesizing BTBF aromatic amine derivatives, in which commercialized raw materials on the market are used, and after etherification, ring closure, bromination, and coupling reaction, target pr...
WO/2022/266427A1	4-(ARYL-METHYL-AMINO)-QUINAZOLINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of Formula (I) and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the co...
WO/2022/266426A1	6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the c...
WO/2022/266458A1	6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the c...
WO/2022/266425A1	3-CYANO-QUINOLINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the c...
WO/2022/263548A1	3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS The present invention relates to certain 3-substituted 1 H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease or medic...
WO/2022/263604A1	SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds PPA that, inter alia, inhibit cyclin-depe...
WO/2022/262838A1	DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS Provided are deuterated compounds of Formula (I), or Formula (I'), or a salt thereof, wherein at least one of R 1 to R 6 is D (Deuterium atom), and X 0, Y, and R is defined herein. Also provided are methods of using such compounds to mod...
WO/2022/266193A1	BICYCLIC COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2022/266015A1	FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...

Matches 401 - 450 out of 9,425	< 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >